Oramed Pharmaceuticals is a biotechnology business based in the US. Oramed Pharmaceuticals shares (ORMP) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.38 – an increase of 2.15% over the previous week.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.38 |
|---|---|
| 52-week range | $1.67 - $3.67 |
| 50-day moving average | $2.39 |
| 200-day moving average | $2.52 |
| Wall St. target price | $3.25 |
| PE ratio | 4.5686 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.51 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.38 from 2024-10-14
| 1 week (2024-10-09) | -0.83% |
|---|---|
| 1 month (2024-09-16) | -4.03% |
| 3 months (2024-07-16) | -7.03% |
| 6 months (2024-04-16) | -0.83% |
| 1 year (2023-10-16) | 9.17% |
|---|---|
| 2 years (2022-10-14) | -61.86% |
| 3 years (2021-10-15) | 22.06 |
| 5 years (2019-10-16) | 3.14 |
Valuing Oramed Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Oramed Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Oramed Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 5x. In other words, Oramed Pharmaceuticals shares trade at around 5x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Gross profit TTM | $2.7 million |
|---|---|
| Return on assets TTM | -4.72% |
| Return on equity TTM | 12.7% |
| Profit margin | 0% |
| Book value | $4.36 |
| Market Capitalization | $95 million |
TTM: trailing 12 months
We're not expecting Oramed Pharmaceuticals to pay a dividend over the next 12 months.
Oramed Pharmaceuticals's shares were split on a 1:12 basis on 22 January 2013. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Oramed Pharmaceuticals shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Oramed Pharmaceuticals shares which in turn could have impacted Oramed Pharmaceuticals's share price.
Over the last 12 months, Oramed Pharmaceuticals's shares have ranged in value from as little as $1.67 up to $3.67. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oramed Pharmaceuticals's is 1.762. This would suggest that Oramed Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.